Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 2
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Refractory Moderate-to-Severe Systemic Lupus Erythematosus With Lupus Nephritis (RECLAIM-LN)
The primary objective of this trial is to evaluate the efficacy and safety of FT819, comprised of allogeneic T cells that express a CD19-targeted CAR, followin…
Lupus NephritisSystemic Lupus ErythematosusSLE - Systemic Lupus Erythematosus+2 more
Estimated
~$10 – $8,750
Fate TherapeuticsNCT07570862
Phase 1
Safety and Efficacy of ONTO1 in Lupus
ONT01 is a drug that is being studied for the treatment of Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) and is not approved by the FDA. The purp…
Lupus Nephritis (LN)Lupus Nephritis - WHO Class IIILupus Nephritis - WHO Class IV+5 more
Estimated
~$10 – $6,250
Hospital for Special Surgery, New YorkNCT07107659